Discontinuation rates due to adverse events for patients randomized to placebo or orforglipron were 4.8% (orforglipron from Wegovy), 7.6% (placebo from Wegovy), 7.2% (orforglipron from Zepbound) and 6.3% (placebo from Zepbound)
Will these pills be available to people without diabetes
de Bari O, Wang HH, Portincasa P, Paik CN, Liu M, Wang DQ
[9] [10] Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish with continued use
However, their impact on atherosclerotic plaque progression remains under investigation
If an agent, such as PPA, that suppressed mitochondrial function was present in vivo but not in vitro , mitochondrial function in the muscle, but not the fibroblast culture, would be more compromised